Today, the adoptive transfer of tumor-infiltrating lymphocytes combined with total-body irradiation, lymphodepleting chemotherapy, and high-dose IL-2 achieve response rates as high as 70% in patients with metastatic melanoma (14). This evidence concerns the gene IL2 and metastatic melanoma.